Drug intelligence / Profile preview

011516X

Development stage: Phase 3
Lead developer: AbbVie
Modality: Small Molecules
Administration: Ophthalmic

Overview

011516X is a new artificial tear formulation being investigated in clinical trials. It is being compared with established artificial tear products such as Systane Ultra Multidose and REFRESH PLUS to evaluate its efficacy and safety.

Other names: New Artificial Tear Formulation

Beyond the preview

Go deeper on 011516X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 011516X.

Explore the full profile